peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma

Hansa Medical listed on First North

17 Oct 2007, 08:00
Regulatory information

Trading of the Hansa Medical share will commence today, October 17, 2007, on First North under the ticker symbol HMED. One trading unit comprises 500 shares. Hansa Medical’s certified adviser is Kaupthing Bank.In September and October, Hansa Medical successfully implemented a new share issue targeting the general public, comprising 3.8 million shares at an issue price of SEK 10. The issue, which generated considerable interest, was fully subscribed and enabled Hansa Medical to raise SEK 38 M before issue expenses. The proceeds of the issue will be used to finance a clinical development plan for Hansa Medical’s lead project, IdeS, and key investments in two smaller projects. The number of shares in Hansa Medical is 3,924,714, of which 36 percent is owned by the company’s Chairman of the Board, Bo Håkansson, through a holding company. Hansa Medical Board members Stina Gestrelius and Per Belfrage, CEO Emanuel Björne, Project Manager Anita Tocaj and research partner Professor Lars Björck are also shareholders in Hansa Medical.About First North First North is an alternative marketplace for small growth companies that provides visibility and ease of access to northern Europe’s capital market. First North is part of the OMX Nordic Exchange Stockholm.For more information, please contact:Emanuel Björne, CEOTelephone: +46 40 630 76 04Mobile: +46 707 17 54 77E-mail: emanuel.bjorne@hansamedical.com